• Home
  • >>>>>>>>>>>>> 2026 & BEYOND MASTER PLAN >>>>>>>>>>>>>>>>
  • Virtual Data Room (VDR) for Strategic Customized Slide Decks
  • TRAINABLE DATA ASSETS IN CORPORATE LEGACY & ORGANIZATION’s STRATEGIC MEMORY (2012 – 2025)
  • 2.0 LPBI Executive Summary
  • 1.0 LPBI Executive Summary
  • Founder’s Vision
  • Portfolio of IP Assets
  • Knowledge PORTALS System (KPS)
  • 1.0 LPBI – 2012-2020 VISTA
  • LPBI Group’s History
  • 2.0 LPBI – 2021-2025 VISION
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder’s Bio
  • Funding, Deals & Partnerships
  • 1.0 LPBI Group News
  • 1.0 LPBI CALENDAR
  • 2.0 LPBI Group News
  • Testimonials about LPBI
  • DrugDiscovery @LPBI Group
  • Medical 3D Printing
  • e-VOICES Podcasting
  • LPBI Newsletters
  • Customer Surveys
  • Health Care INVESTOR’s Corner ($)
  • 2021 Summer Internship Portal
  • 2021-2025 Medical Text Analysis (NLP)
  • Artificial Intelligence: Genomics & Cancer
  • Blockchain Transactions Network Ecosystem
  • 1.0 LPBI Brochure
  • 2.0 LPBI Brochure
  • 2.0 LPBI – Calendar of Zooms
  • Coronavirus, SARS-CoV-2 Portal
  • LPBI India
  • SOP Web STAT
  • Synthetic Biology in Drug Discovery
  • Certificate One Year
  • NFT: Redefined Format of IP Assets
  • Audio English-Spanish: BioMed e-Series
  • Five Bilingual BioMed e-Series
  • Press Releases
  • Intangibles CIM
  • BioMed Audio Podcast Library @LPBI Group
  • Medical School Education: Use of LPBI Group’s Contents
  • ChatGPT + Wolfram PlugIn
  • Medicine with GPT-4 & ChatGPT
  • AGI, generativeAI, Grok, DeepSeek & Expert Models in Healthcare
  • Multimodal Healthcare Foundation Model
  • Cell Therapy in Regenerative Medicine, 2026 and Beyond
  • Contact Us

Leaders in Pharmaceutical Business Intelligence Group, LLC, Doing Business As LPBI Group, Newton, MA

Healthcare analytics, AI solutions for biological big data, providing an AI platform for the biotech, life sciences, medical and pharmaceutical industries, as well as for related technological approaches, i.e., curation and text analysis with machine learning and other activities related to AI applications to these industries.

Feeds:
Posts
Comments

Podcast with Dr. Sudipta Saha, PhD, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Gail S. Thornton, PhDc

Podcast with Dr. Sudipta Saha, PhD, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Gail S. Thornton, PhDc

12/31/2020

Interview with Dr. Sudipta Saha, Assistant Professor in Physiology at Amity University, Noida, India by Gail S. Thornton

Reporter: Gail S. Thornton, M.A.

Welcome to E-Voices, our podcast series exploring cutting-edge science and medical topics, sponsored by the Leaders in Pharmaceutical Business Intelligence. I’m Gail Thornton, your host for this podcast.

Today’s guest is Dr. Sudipta Saha, Ph.D., who is an Assistant Professor in Physiology at Amity University in Noida, India, since 2017.

Dr. Saha completed his Ph.D. in Reproductive Biology from CSIR-Indian Institute of Chemical Biology in 2008 under the supervision of Dr. G.C. Majumder. He began his postdoctoral research in the same lab and later moved to Taiwan to work as a postdoctoral researcher at Chang Gung Memorial Hospital with Dr. Yu Cheng Pei and, subsequently, at Chang Gung University with Prof. Pin Ouyang. He later returned to India and was granted a Senior Research Associate Fellowship from the Council of Scientific and Industrial Research (CSIR), working as a Scientists’ Pool Officer during 2015 through 2017 at the same Institute where he did his Ph.D.

During his first postdoctoral tenure in Taiwan with Dr. Yu Cheng Pei, he had the opportunity to visit and receive training at the lab of Dr. Sliman Bensmaia at University of Chicago in the United States. During his postdoctoral research in Taiwan, he was part of a team that made an instrument that can analyze visual and tactile motion integration in the somatosensory cortex of the brain. This research was published in the journal Sensors.

In his second postdoctoral tenure in Taiwan he worked on regulation of cell division. More specifically, his work was on localization of Cep55 and FLJ25439 proteins during cytokinesis. A part of the research was published in the journal Cell Cycle. Cep55 knockout mice also were developed in the same lab and maintained by him to find some interesting phenotypes.

During his Ph.D. research, he created a novel spectrophotometer-based instrument system to determine and analyze the vertical movement of spermatozoa, including vertical velocity. Vertical velocity is a better index of sperm health as it is recorded against the gravity. This research occurred with the help through an industrial collaboration, which then led to a patent granted in India and data published later in the journal of quantitative cell science, Cytometry Part A.

Additionally, Dr. Saha isolated a novel protein from goat blood that can enhance the sperm forward motility to a great extent and much more than any other known motility promoters like theophylline or bicarbonate. This protein also helped in maintaining sperm motility in room temperature for a long duration. The antibody of this protein also inhibited sperm-egg interaction. This research was published in Fertility and Sterility.

Both Dr. Saha’s Ph.D. research topics have potential use in fertility management and conservation of endangered species. The instrument design brought several awards, including two best poster awards, the India Innovation Pioneers Challenge Award from Indo-U.S. Science and Technology Forum and the Biotech Idea to Innovation Award from the British Council. Because of these recognitions, he received additional training at the lab of Dr. Uday Kishore in Brunel University, London, U.K.

For the past eight years, he has been an author, curator and reporter of numerous scientific articles for Leaders in Pharmaceutical Business Intelligence (LPBI) Group, a pharmaceutical media venture with several cloud-based products. LPBI Group’s products include an open-access online scientific journal called PharmaceuticalIntelligence.com, a BioMed e-Series of 16 volumes in Medicine, real-time press coverage of biotech and medical conferences, and a podcast library of Interviews with key opinion leaders, all involving a team of experts, authors and writers in science and medicine.

Dr. Saha served as an Editor on several volumes in LPBI’s BioMed e-Series, namely on gene editing, genomics, cardiovascular disease and regenerative and translational medicine. He has published 14 journal articles, four book chapters and eight e-Books.

He is one of six authors of a recently published book (In Press), Microbial Pathogenesis: Infection and Immunity, by Springer Nature in New York. In this book, he co-authored a chapter on the COVID-19 pandemic with Dr. Uday Kishore. The title of the chapter is: SARS-CoV-2: Pathogenic mechanisms and host immune response.

Dr. Saha has received a research grant from Science and Engineering Research Board, Department of Science and Technology, India, to work on the isolation and characterization of the receptor of the motility stimulating protein that he isolated during his Ph.D. research. Two Ph.D. students are working in his lab presently.

He is a reviewer of Plos One Journal and he is a life member of the Indian Science Congress Association and the Society of Biological Chemists in India.

###

 

Share this:

  • Share on X (Opens in new window) X
  • Share on LinkedIn (Opens in new window) LinkedIn
  • Share on Facebook (Opens in new window) Facebook
  • Print (Opens in new window) Print
  • Email a link to a friend (Opens in new window) Email

Like this:

Like Loading…

  • Follow Blog via Email

    Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,041 other subscribers
  • Recent Posts

    • FDA Moves Forward With Its Guidance Framework for Rare Disease Trials: 2026 August 3, 2026
    • Artificial Intelligence TRANSFORMS Medicine, Biotech and Healthcare, How? August 3, 2026
    • In Memoriam: Nobel Laureate J. Michael Bishop for discovery of Retroviral Oncogenes July 31, 2026
    • Companies Actively Engaging Artificial Intellegence for Drug Design: 2026 July 31, 2026
    • AI-Native Drug Discovery Landscape 2026 – How LPBI Group Differentiates in the New Era of Foundation Models July 19, 2026
    • In Memoriam: In Remembrance of Cancer Researchers who passed in 2026 July 13, 2026
    • Urgent Request for Action on Proposed Rule Affecting Federal Funding Grant Review July 7, 2026
    • 2026 Tang Prize in Biopharmaceutical Science Awarded to Three Pioneers of Cellular Immunotherapy Revolutionizing Treatments for Blood Cancers and Solid Tumors July 5, 2026
    • Protected: KOL on Competitive Dynamics: LPBI Group’s Founder’s Radar Screens on AI-in-Health, Life Sciences & BioPharma June 15, 2026
    • Tumor Infiltrating Lymphocytes (TIL) as a first of kind FDA approved immunotherapy for cancer June 12, 2026
  • Archives

  • Categories

  • Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    • 1 2012pharmaceutical
    • 1 sjwilliamspa

Powered by WordPress.com.

WPThemes.


Loading Comments...
%d